AIM’s Latest Newsletter: The Research Edition, July 2023

Published:  
08/01/2023
Categories:  
Blog - Melanoma360
 | 
Melanoma Research
Image

This month’s newsletter focuses on the latest news and scientific breakthroughs in melanoma research.

This edition features:

  • Letter from AIM’s President, Sam Guild
  • Notes From the Lab: Novel Targets for Immune Checkpoint Inhibitors
    By Paul Bunk, Ph.D. candidate, Cold Springs Harbor Laboratory
  • In Plain English: Neoadjuvant Therapy for Melanoma, and How We Got Here
    By Kim Margolin, M.D., FACP, FASCO
  • Clinical Trials Catch Up: An Interview with Joshua M.V. Mammen, M.D., Ph.D., F.A.C.S.
    By Alicia Rowell, Vice President, AIM at Melanoma

Recent Posts

Featured image for “Caring Through Loss: A Conversation on Bereavement”
Sep. 09, 2025

Caring Through Loss: A Conversation on Bereavement

Featured image for “Advocating for Patients: Letter to the FDA on RP1 Treatment Access”
Sep. 05, 2025

Advocating for Patients: Letter to the FDA on RP1 Treatment Access

Featured image for “Hope on the Horizon: Clinical Trials & Progress in Ocular/Uveal Melanoma”
Sep. 04, 2025

Hope on the Horizon: Clinical Trials & Progress in Ocular/Uveal Melanoma

Featured image for “Back to AIM: Advocacy, Walks, and Fall Initiatives in Melanoma”
Aug. 26, 2025

Back to AIM: Advocacy, Walks, and Fall Initiatives in Melanoma

Featured image for “Side Effect Central – Cutaneous Squamous Cell Carcinoma and Keratoacanthoma”
Aug. 26, 2025

Side Effect Central – Cutaneous Squamous Cell Carcinoma and Keratoacanthoma

Filter by Tag